靶向腺苷介导的「别吃我信号」通过抗CD20单克隆抗体增强抗淋巴瘤免疫
该研究利用同基因B细胞淋巴瘤模型和小鼠异种移植模型,发现细胞外腺苷通过A2A受体(而非A2B受体)抑制抗CD20单克隆抗体的疗效,腺苷信号损害巨噬细胞抗体依赖性细胞吞噬作用(ADCP)并限制抗淋巴瘤CD8+ T细胞产生,药物抑制A2AR可克服腺苷对利妥昔单抗ADCP的负调控;CD39过表达与弥漫性大B细胞淋巴瘤患者不良预后及利妥昔单抗临床前疗效降低相关。
要点
- 宿主A2AR缺失而非A2BR缺失显著改善抗CD20单抗对淋巴瘤的控制。
- 腺苷信号损害巨噬细胞ADCP并限制抗淋巴瘤CD8+ T细胞产生。
- CD39过表达与DLBCL患者不良预后及利妥昔单抗临床前疗效降低相关。
核心结论
- 腺苷作为「别吃我信号」起作用,可能是增强抗淋巴瘤免疫的潜在靶点。
研究设计与样本
- 研究使用同基因B细胞淋巴瘤模型和小鼠异种移植淋巴瘤模型,并在弥漫性大B细胞淋巴瘤患者中分析CD39表达的预后影响。
主要发现
- 宿主A2AR缺失而非A2BR缺失显著改善抗CD20单抗治疗的淋巴瘤控制。
- 髓系细胞中条件性敲除A2AR、其次在NK细胞中敲除A2AR,增强抗CD20单抗的疗效。
- 腺苷信号损害巨噬细胞抗体依赖性细胞吞噬作用(ADCP)并限制抗淋巴瘤CD8+ T细胞产生。
- 药理学抑制A2AR在异种移植淋巴瘤模型中克服腺苷对利妥昔单抗ADCP的负调控。
- CD39过表达对弥漫性大B细胞淋巴瘤患者预后及利妥昔单抗临床前疗效均显示负面影响。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A growing body of evidence suggests that macrophage immune checkpoint molecules are potential targets in the era of cancer immunotherapy. Here we showed that extracellular adenosine, an abundant metabolite in the tumor microenvironment, critically impedes the therapeutic efficacy of anti-CD20 monoclonal antibodies (mAbs) against B-cell lymphoma. Using a syngeneic B-cell lymphoma model, we showed that host deficiency of adenosine 2A receptor (A2AR), but not A2BR, remarkably improved lymphoma control by anti-CD20 mAb therapy. Conditional deletion of A2AR in myeloid cells, and to a lesser extent in NK cells, augmented therapeutic efficacy of anti-CD20 mAb. Indeed, adenosine signaling impaired antibody-mediated cellular phagocytosis (ADCP) by macrophages and limited the generation of anti-lymphoma CD8+ T cells. Pharmacological inhibition of A2AR overcame the adenosine-mediated negative regulation of ADCP by rituximab in a xeno-transplanted lymphoma model. Moreover, aberrant overexpression of CD39, an apical ecto-enzyme for adenosine generation, showed a negative impact on prognosis in patients with diffuse large B-cell lymphoma, as well as on preclinical efficacy of rituximab. Together, adenosine acts as a "don't eat me signal", and may be a potential target to harness anti-lymphoma immunity.
引用
- Nakamura K, Casey M, Oey H, et al. Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. Leukemia. 2020. PMID: 32269319. doi:10.1038/s41375-020-0811-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。